First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir)
Dateline City:
WHITEHOUSE STATION, N.J.
ONCEMRK Study Globally Enrolling Treatment-Naïve Adults with HIV-1
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the first patient has been enrolled in the
company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a
once-daily investigational formulation of ISENTRESS®
(raltegravir), known as reformulated raltegravir, as part of combination
HIV therapy for treatment-naïve HIV-1-infected adults.
Language:
English
Contact:
MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news